MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis

Recruiting N/A Interventional Study
Multiple Sclerosis Magnetic Resonance Spectroscopy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
50 (estimated)
Sponsor
Poitiers University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The transition from relapsing-remitting multiple sclerosis to secondarily progressive multiple sclerosis (SPMS) is difficult to identify. Typically, SPMS is diagnosed retrospectively, with a significant delay, on the basis of a clinical history of progressive worsening, independent of relapses. Thus, SPMS is often associated with a considerable period of diagnostic uncertainty. The use of ultra-h…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years, * Duration of disease ≤ 25 years, * Irreversible disability ≤ 7 (permanent wheelchair use) on the EDSS scale Exclusion Criteria: * Other progressive neurological disease, * Isolated radiologic syndrome (RIS), * Severe psychiatric pathology not in balance, * C…
Contacts

Amelie Dos Santos, Dr

+33.5.49.44.44.46

amelie.dos-santos@chu-poitiers.fr

CONTACT